Archer Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023.

The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product.

The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.